Interleukin-6: a candidate mediator of human prostate cancer morbidity (Q41362792)

29 September 2017

title

Interleukin-6: a candidate mediator of human prostate cancer morbidity (English)

1 reference

29 September 2017

1 reference

Twillie DA

1

1 reference

29 September 2017

Eisenberger MA

2

1 reference

29 September 2017

Carducci MA

3

1 reference

29 September 2017

Hseih WS

4

1 reference

29 September 2017

Kim WY

5

1 reference

29 September 2017

Simons JW

6

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 March 1995

1 reference

29 September 2017

1 reference

29 September 2017

volume

45

1 reference

29 September 2017

issue

3

1 reference

29 September 2017

page(s)

542-549

1 reference

Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Evidence for the involvement of interleukin 6 in experimental cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

p53 oncogene mutations in three human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

1 reference

7 January 2021

Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

The mechanism of hepatic cellular injury in sepsis: an in vitro study of the implications of cytokines and neutrophils in its pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980034-X

7 January 2021

10.1016/S0090-4295(99)80034-X

Identifiers

DOI

1 reference

29 September 2017

1 reference